| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 05/06/2004 | WO2003106416A3 Chemical process |
| 05/06/2004 | WO2003104254A3 Novel derivatives of androstane and androstene with ascorbic a cid and use thereof in treating or preventing various conditions, diseases, and disorders |
| 05/06/2004 | WO2003101951A3 Triptolide derivatives for modulation of apoptosis and immunosuppression |
| 05/06/2004 | WO2003097641A3 1h-imidazo[4,5-c] quinoline derivatives in the treatment of protein kinase dependent diseases |
| 05/06/2004 | WO2003096964A3 Means for use in treating diseases correlated with or caused by non-physiological levels of microtubule-associated pp2ac |
| 05/06/2004 | WO2003073828B1 Immunotherapy for prostate cancer using recombinant bacille calmette-guerin expressing prostate specific antigens |
| 05/06/2004 | WO2003072801A3 Compositions and method for regulation of calcium-dependent signalling in brain |
| 05/06/2004 | WO2003051837A8 Tetrahydrocarbozole derivatives as ligands for g-protein coupled receptors (gpcr) |
| 05/06/2004 | WO2003051304A3 Bioadhesive drug delivery system with enhanced gastric retention |
| 05/06/2004 | WO2003050502A9 Prospective identification and characterization of breast cancer stem cells |
| 05/06/2004 | WO2003025019A9 Anti-pdgf antibodies and methods for producing engineered antibodies |
| 05/06/2004 | WO2003022298A3 Use of a protein of the crmp family for treating diseases related to the immune system |
| 05/06/2004 | WO2003016351B1 N - cam related compounds modulating cell groth |
| 05/06/2004 | WO2003011903A3 Identification of specific tumor antigens by means of the selection of cdna libraries with sera |
| 05/06/2004 | WO2003009773A8 Removable stent and method of using the same |
| 05/06/2004 | WO2003005971A8 Tetracycline compounds having target therapeutic activities |
| 05/06/2004 | WO2003004467A3 Thiazole benzamide derivatives and pharmaceutical compositions for inhibiting cell proliferation, and methods for their use |
| 05/06/2004 | WO2002102800A9 5-(2-aminopyrimidin-4-yl) benzisoxazoles as protein kinase inhibitors |
| 05/06/2004 | WO2002096348A3 Product comprising mikanolide, dihydromikanolide or an analogue thereof combined with another anti-cancer agent for therapeutic use in cancer treatment |
| 05/06/2004 | WO2002089800A3 N-aroyl cyclic amine derivatives as orexin receptor antagonists |
| 05/06/2004 | WO2002074251A9 Monoclonal antibody therapy for pancreas cancer |
| 05/06/2004 | WO2002057222A9 Thiol-based naaladase inhibitors |
| 05/06/2004 | WO2002022150A3 Medicament containing activated antithrombin iii |
| 05/06/2004 | WO2002020512A9 Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation |
| 05/06/2004 | WO2001074296A3 Treatment of non-solid mammalian tumors with vascular endothelial growth factor receptor antagonists |
| 05/06/2004 | US20040087800 Spirooxindole derivatives are analgesics for the treatment of chronic pain. |
| 05/06/2004 | US20040087791 Bis(substituted propynyl)-substituted benzenes, pyridines, pyrimidines, pyrazines, pyridines, furans and pyrroles; e.g., 3,5-bis-(3-(4-aminomethylbenzylaminocarbonyloxy)prop-1-ynyl)--1 -hydroxymethylbenzene |
| 05/06/2004 | US20040087784 Neuronal serine-threonine protein kinase |
| 05/06/2004 | US20040087778 Modified peptides as therapeutic agents |
| 05/06/2004 | US20040087775 Process for production diphtheria toxin |
| 05/06/2004 | US20040087774 Comprises tumor necrosis factor receptor associated factor-(TRAF) inhibitor for diagnosis, prevention and tratment of tumors associated wit h epstein-barr virus |
| 05/06/2004 | US20040087657 Treatment of neurodegenerative diseases and cancer of the brain using histone deacetylase inhibitors |
| 05/06/2004 | US20040087652 Induction cell differentiation; apoptosis |
| 05/06/2004 | US20040087649 Cytotoxic agents comprising taxanes and their therapeutic use |
| 05/06/2004 | US20040087640 Administering by mouth; cyclooxygenase inhibitor; controlling particle size |
| 05/06/2004 | US20040087635 Administering insulin sensitizer; benign prostatic hyperplasia |
| 05/06/2004 | US20040087634 Antitumor agents; plant safening agents |
| 05/06/2004 | US20040087627 Decarboxylase inhibitors; cardiovascular diosrders; antidiabetic agents; anticancer agents; dietetics |
| 05/06/2004 | US20040087626 Substituted benz-azoles and methods of their use as inhibitors of Raf kinase |
| 05/06/2004 | US20040087624 Analgesics; antiinflammatory agents; immunology; bone disorders; neurodegradation diseases |
| 05/06/2004 | US20040087623 Pyrazole derivatives against tgf overexpression |
| 05/06/2004 | US20040087611 Cancer treatment by combination therapy |
| 05/06/2004 | US20040087610 Method and composition for the treatment of cancer |
| 05/06/2004 | US20040087609 Process for producing camptothecin |
| 05/06/2004 | US20040087601 Pyrimidine derivatives as IL-8 receptor antagonists |
| 05/06/2004 | US20040087598 2-pyridinyl-6,7,8,9-tetrahydropyrimido{1,2-a}pyrimidin-4-one and 7-pyridinyl-1,3-dihydoimidazo{1,2-a}pyrimidin-5(1h)one derivatives |
| 05/06/2004 | US20040087594 Diaminothiazoles having antiproliferative activity |
| 05/06/2004 | US20040087588 Parp inhibitors |
| 05/06/2004 | US20040087582 Anticaogulants; cardiovascular disorders; Factor x inhibitors; antiinflammatory agents |
| 05/06/2004 | US20040087568 Substituted anthranilic amide derivatives and methods of use |
| 05/06/2004 | US20040087567 Anticancer agents; particularly liver cancer |
| 05/06/2004 | US20040087566 Enzyme inhibitors; anticancer agents |
| 05/06/2004 | US20040087557 Treating muscle wasting with selective androgen receptor modulators |
| 05/06/2004 | US20040087555 Phosphohalohydrins, process for the production thereof and use thereof |
| 05/06/2004 | US20040087552 Pyrrolidine modulators of ccr5 chemokine receptor activity |
| 05/06/2004 | US20040087550 Composition comprising bisphosphonates for prevention and/or treatment of metabolic diseases of bones, process for preparing such composition and use thereof |
| 05/06/2004 | US20040087548 Anticancer agents and treating immune disorders |
| 05/06/2004 | US20040087547 Orally administered antitumor agents |
| 05/06/2004 | US20040087538 Nucleic acids containing unmethylated cytosine-guanine dinucleotides activate lymphocytes and redirect an immune response from th2 to th1 |
| 05/06/2004 | US20040087532 Vaccine comprising antigen presenting cells loaded with at least two tumor antigens and/or tumor antigen derived peptides |
| 05/06/2004 | US20040087531 Inhibiting expression of gene tpt1 |
| 05/06/2004 | US20040087525 Polypeptide-human rna binding protein 19 and the polynucleotide encoding it |
| 05/06/2004 | US20040087524 Agent for postoperative use after removal of bone tumours |
| 05/06/2004 | US20040087510 Cardiovascular diseases and disorders; sustained delivery of nitric oxide |
| 05/06/2004 | US20040087497 CD10-activated prodrug compounds |
| 05/06/2004 | US20040087490 Leucine with isoleucine, lysine, methionine, phenylalanine, threonine, tryptophan, valine and/or histidine; tumor induced weight loss; kits |
| 05/06/2004 | US20040086999 Modified amino acid sequences for prevention and treatment of cancer, vision defects and inflammatory diseases |
| 05/06/2004 | US20040086988 Enzyme catalyst; polypeptides; crystal structure |
| 05/06/2004 | US20040086974 Comprises human tumor suppressor protein for treatment and prevention of cell proliferative disorders; antitumor/anticarcinogenic/antiproliferative agents |
| 05/06/2004 | US20040086923 Comprises polypeptide with carbamoyl phosphate synthase (CPS) activity for identifying modulators which prevent and/or treat cancer and metabolic disorders |
| 05/06/2004 | US20040086913 Human genes and gene expression products XVI |
| 05/06/2004 | US20040086905 Lipid-associated molecules |
| 05/06/2004 | US20040086904 Identifying modulators which suppress synthesis of secreted and/or membrane protein for prevention and treatment of allergic,inflammatory, skin, cardiovascular, nervous system and cancer disorders |
| 05/06/2004 | US20040086899 Compromises nuclelotide sequences coding polypeptides associated with elongation of fatty acid chains for treatment and prevention of skin, cardiovascular, inflammatory, gastrointestinal, respiratory system and bone disorders |
| 05/06/2004 | US20040086877 Multi-mode directi memory access controller and method |
| 05/06/2004 | US20040086863 Comprises pleckstrin homology domain-interacting protein (PHI Protein) for identifying modulator and treatment for cancer and insulin response disorders |
| 05/06/2004 | US20040086851 Anticancer agents |
| 05/06/2004 | US20040086522 Strategies to prevent autoimmune disease by vaccination with vaccines based upon Epstein-Barr virus |
| 05/06/2004 | US20040086521 Method for the identification of antigenic peptides |
| 05/06/2004 | US20040086518 Universal vaccine and method for treating cancer employing telomerase reverse transcriptase |
| 05/06/2004 | US20040086516 Inhibiting antigen presentation, comprising the step of supplying to an antigen-presenting cell, such as a dendritic cell, or precursor cell, a modulator, preferably an enhancer, of Toll-related receptor signalling |
| 05/06/2004 | US20040086514 Based on the finding of a specific Helicobacter pylori receptor in the human gastric epithelium; a glycolipid, lactotetraosylceramide, exclusively found in the human gastrointestinal tract |
| 05/06/2004 | US20040086505 Derived from human placenta |
| 05/06/2004 | US20040086503 High-affinity human anti-IGF-IR antibodies that could be used to treat diseases in humans |
| 05/06/2004 | US20040086502 Has a binding affinity for a target antigen which is at least about two fold stronger than the binding affinity of the parent antibody for said antigen |
| 05/06/2004 | US20040086500 Murabutide, an analog of muramyl dipeptide, induces the production of cytokines or other factors not identified to date, which have a suppressor activity on HIV |
| 05/06/2004 | US20040086498 Cancer therapy |
| 05/06/2004 | US20040086492 Achieves a remarkable improvement in the effect of the treatment of a tumor such as cancer by administering activated lymphocytes over a specific period of time before or after the implementation of photodynamic therapy |
| 05/06/2004 | US20040086485 Viral vector sequences in plasmid form delivered in-vivo to generate vector producing cells |
| 05/06/2004 | US20040086479 Can be chemically modified for different biomedical applications such as tissue engineering applications, wound management, contrast agents vehicles, drug delivery vehicles, etc. |
| 05/06/2004 | US20040086460 Chelate metal ions that can be detected either by their paramagnetic or radioactive properties; diagnostic and therapeutic agents |
| 05/06/2004 | EP1416279A1 Methods for diagnosis and therapy of pancreatic cancer and composition useful therein |
| 05/06/2004 | EP1415997A1 Polypeptides relating to signal transfer of advanced glycation end product receptor |
| 05/06/2004 | EP1415994A1 Retinal pigmented epithelium derived neurotrophic factor |
| 05/06/2004 | EP1415987A1 Nitrogenous aromatic ring compounds |
| 05/06/2004 | EP1415659A1 BAFF, inhibitors thereof and their use in the modulation of the B-cell response |
| 05/06/2004 | EP1415653A2 Use of progesterone or an agonist thereof for the inhibition of steroid synthesis |
| 05/06/2004 | EP1415650A1 Nutritional composition for the prevention and treatment of cachexia and anorexia |
| 05/06/2004 | EP1415005A2 Endogenous retroviruses up-regulated in prostate cancer |
| 05/06/2004 | EP1414965A2 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |